This 52-week RCT (n=284 adults with obesity, 90% women) from Vestfold Hospital and Roede AS demonstrates that a structured 16-week rapid weight-loss protocol (<1000 kcal/day initially) produced superior one-year total body weight loss and higher rates of clinically meaningful targets (BMI ≤27 or WHtR ≤0.53) compared with gradual caloric restriction. As an investigator-initiated randomized trial rather than observational data, it carries stronger causal weight than the historical studies that fueled the 'slow-and-steady' consensus. The identical 36-week maintenance phase for both arms isolates the initial velocity of loss as the key differentiator. Prior meta-analyses relying on self-reported or non-randomized cohorts likely conflated rapid loss with unsustainable crash diets; here, food-based programs aligned with Norwegian dietary guidelines minimized that confound. For the millions now using GLP-1 receptor agonists, these results suggest that pairing pharmacotherapy with aggressive early caloric control could accelerate target achievement and reduce cumulative exposure time to obesity-related risk. However, the trial's predominantly female sample and absence of body-composition or muscle-mass endpoints leave open questions about sarcopenia risk under very-low-calorie conditions. No industry conflicts were declared beyond the commercial-program collaboration, strengthening credibility relative to many diet-industry-funded studies.